Таргетирование NMDAR/AMPAR — перспективный подход фармакокоррекции депрессивных расстройств

Куркин Д.В., Морковин Е.И., Бакулин Д.А., Горбунова Ю.В., Иванова О.В., Павлова Е.В., Зверева В.И., Джавахян М.А., Крысанов И.С., Колосов Ю.А., Заборовский А.В., Стрыгин А.В., Петров В.И., Белый П.А., Заславская К.Я., Мальцев Д.В., Скрипка М.О. Таргетирование NMDAR/AMPAR — перспективный подход фармакокоррекции депрессивных расстройств. Журнал неврологии и психиатрии им. С.С. Корсакова. 2024;124(5):22‑30.
Kurkin DV, Morkovin EI, Bakulin DA, Gorbunova YuV, Ivanova OV, Pavlova EV, Zvereva VI, Dzhavakhyan MA, Krysanov IS, Kolosov YuA, Zaborovsky AV, Strygin AV, Petrov VI, Beliy PA, Zaslavskaya KY, Maltsev DV, Skripka MO. Targeting NMDAR/AMPAR: a promising pharmacotherapeutic approach for depressive disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(5):22‑30. (In Russ.)
https://doi.org/10.17116/jnevro202412405122

Использование инфографики авторами научных работ

Закрыть метаданные

Рекомендуем статьи по данной теме:

Влияние симптомов депрессии на постморбидную адаптацию пациентов, перенесших SARS-CoV-2-инфекцию (оценка с позиции модели мультиморбидности). Журнал неврологии и психиатрии им. С.С. Корсакова. 2023;(3):70-74

Особенности психоэмоциональной сферы и качества жизни у пациентов с вестибулярной мигренью. Журнал неврологии и психиатрии им. С.С. Корсакова. 2023;(4):48-52

Клинико-психологический профиль и качество жизни пациентов с постковидным синдромом. Журнал неврологии и психиатрии им. С.С. Корсакова. 2023;(4):53-58

Влияние моторных и вегетативных нарушений на выраженность болевого синдрома у пациентов с I—III стадиями болезни Паркинсона. Журнал неврологии и психиатрии им. С.С. Корсакова. 2023;(4):59-67

Оптимизация лечения депрессии назначением этилметилгидроксипиридина сукцината (Мексикор). Журнал неврологии и психиатрии им. С.С. Корсакова. 2023;(4):78-84

Нозогенные психосоматические расстройства у пациентов с кожными заболеваниями. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2023;(4-2):36-43

Влияние значимых стрессовых событий на течение первичных цефалгий. Российский журнал боли. 2023;(1):26-32

Факторы, влияющие на неблагоприятное течение мигрени во II—III триместрах беременности. Российский журнал боли. 2023;(1):39-46

Валидация русскоязычной версии Госпитальной шкалы тревоги и депрессии в общей популяции. Профилактическая медицина. 2023;(4):7-14

Кардиометаболические и психокогнитивные особенности постковидного периода у больных с фибрилляцией предсердий. Профилактическая медицина. 2023;(4):43-50

Депрессия является одной из лидирующих причин инвалидизации и снижения трудоспособности во всем мире. Моноаминовая теория патогенеза депрессии оставалась главенствующей на протяжении многих десятилетий, однако препараты, разработанные на ее основе, имеют ограниченную эффективность. Изучение иных механизмов возникновения данной патологии может пролить свет на новые пути фармакокоррекции этого заболевания. Влияние на глутаматергические пути в центральной нервной системе, в частности модуляция рецепторов N-метил-D-аспартата и α-амино-3-гидрокси-5-метил-4-изоксазолпропионовой кислоты, показывает многообещающие результаты. В данном обзоре представлены некоторые существующие препараты с глутаматергической активностью, а также новые разработки на ее основе для повышения эффективности лекарственной терапии депрессивных заболеваний.

Ключевые слова:

депрессия

серотонин

глутамат

NMDA

AMPA

кетамин

Авторы:

Куркин Д.В.

ORCID: 0000-0002-1116-3425

Морковин Е.И.

ФГБОУ ВО «Волгоградский государственный медицинский университет» Минздрава России

ORCID: 0000-0002-7119-3546

Бакулин Д.А.

ФГБОУ ВО «Российский университет медицины» Минздрава России

ORCID: 0000-0003-4694-3066

Горбунова Ю.В.

ФГБОУ ВО «Российский университет медицины» Минздрава России

ORCID: 0000-0002-6416-0500

Иванова О.В.

ФГБОУ ВО «Российский университет медицины» Минздрава России

ORCID: 0000-0003-4333-322X

Павлова Е.В.

ФГБОУ ВО «Российский университет медицины» Минздрава России

ORCID: 0000-0003-0651-3205

Зверева В.И.

ФГБОУ ВО «Российский университет медицины» Минздрава России

ORCID: 0000-0001-5274-3736

Джавахян М.А.

ФГБОУ ВО «Российский университет медицины» Минздрава России

ORCID: 0000-0003-2673-6203

Крысанов И.С.

ФГБОУ ВО «Российский университет медицины» Минздрава России

ORCID: 0000-0002-3541-1120

Колосов Ю.А.

ФГБОУ ВО «Российский университет медицины» Минздрава России

ORCID: 0000-0003-1506-2565

Заборовский А.В.

ФГБОУ ВО «Российский университет медицины» Минздрава России

ORCID: 0000-0002-7923-9916

Стрыгин А.В.

ФГБОУ ВО «Волгоградский государственный медицинский университет» Минздрава России

ORCID: 0000-0002-6997-1601

Петров В.И.

ФГБОУ ВО «Волгоградский государственный медицинский университет» Минздрава России

ORCID: 0000-0002-0258-4092

Белый П.А.

ФГБОУ ВО «Российский университет медицины» Минздрава России

ORCID: 0000-0001-5998-4874

Заславская К.Я.

ФГБОУ ВО «Национальный исследовательский Мордовский государственный университет им. Н.П. Огарева»

ORCID: 0000-0002-7348-9412

Мальцев Д.В.

ФГБОУ ВО «Волгоградский государственный медицинский университет» Минздрава России

ORCID: 0000-0002-2005-6621

Скрипка М.О.

ФГБОУ ВО «Волгоградский государственный медицинский университет» Минздрава России

ORCID: 0000-0002-4173-7143

Дата поступления:

21.12.2023

Дата принятия в печать:

23.01.2024

Список литературы:

Marx W, Penninx BWJH, Solmi M, et al. Major depressive disorder. Nat Rev Dis Primers. 2023;9(1):44. https://doi.org/10.1038/s41572-023-00454-1
Gonda X, Dome P, Neill JC, Tarazi FI. Novel antidepressant drugs: Beyond monoamine targets. CNS Spectr. 2023;28(1):6-15. https://doi.org/10.1017/S1092852921000791
Gaebel W, Zielasek J, Reed GM. Mental and behavioural disorders in the ICD-11: concepts, methodologies, and current status. Psychiatr Pol. 2017;51(2):169-195. https://doi.org/10.12740/PP/69660
Dornquast C, Tomzik J, Reinhold T, et al. To what extent are psychiatrists aware of the comorbid somatic illnesses of their patients with serious mental illnesses? — a cross-sectional secondary data analysis. BMC Health Serv Res. 2017;17(1):162. https://doi.org/10.1186/s12913-017-2106-6
Schramm E, Klein DN, Elsaesser M, et al. Review of dysthymia and persistent depressive disorder: history, correlates, and clinical implications. Lancet Psychiatry. 2020;7(9):801-812. https://doi.org/10.1016/S2215-0366(20)30099-7
Greenberg PE, Fournier AA, Sisitsky T, et al. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry. 2015;76(2):155-162. https://doi.org/10.4088/JCP.14m09298
Steffen A, Nübel J, Jacobi F, et al. Mental and somatic comorbidity of depression: a comprehensive cross-sectional analysis of 202 diagnosis groups using German nationwide ambulatory claims data. BMC Psychiatry. 2020;20(1):142. https://doi.org/10.1186/s12888-020-02546-8
Shukla R, Newton DF, Sumitomo A, et al. Molecular characterization of depression trait and state. Mol Psychiatry. 2022;27(2):1083-1094. https://doi.org/10.1038/s41380-021-01347-z
Bauer M, Severus E, Möller HJ, et al. Task Force on Unipolar Depressive Disorders. Pharmacological treatment of unipolar depressive disorders: summary of WFSBP guidelines. Int J Psychiatry Clin Pract. 2017;21(3):166-176. https://doi.org/10.1080/13651501.2017.1306082
Swetlitz N. Depression’s Problem With Men. AMA J Ethics. 2021;23(7):E586-589. https://doi.org/10.1001/amajethics.2021.586
Bueno-Notivol J, Gracia-García P, Olaya B, et al. Prevalence of depression during the COVID-19 outbreak: A meta-analysis of community-based studies. Int J Clin Health Psychol. 2021;21(1):100196. https://doi.org/10.1016/j.ijchp.2020.07.007
Mazza MG, Palladini M, Poletti S, et al. Post-COVID-19 Depressive Symptoms: Epidemiology, Pathophysiology, and Pharmacological Treatment. CNS Drugs. 2022;36(7):681-702. https://doi.org/10.1007/s40263-022-00931-3
Steffens DC, Fahed M, Manning KJ, et al. The neurobiology of apathy in depression and neurocognitive impairment in older adults: a review of epidemiological, clinical, neuropsychological and biological research. Transl Psychiatry. 2022;12(1):525. https://doi.org/10.1038/s41398-022-02292-3
Karawekpanyawong N, Kaewkitikul K, Maneeton B, et al. The prevalence of depressive disorder and its association in Thai cervical cancer patients. PLoS One. 2021;16(6):e0252779. https://doi.org/10.1371/journal.pone.0252779
Cui R. Editorial: A Systematic Review of Depression. Curr Neuropharmacol. 2015;13(4):480. https://doi.org/10.2174/1570159x1304150831123535
Borbély É, Simon M, Fuchs E, et al. Novel drug developmental strategies for treatment-resistant depression. Br J Pharmacol. 2022;179(6):1146-1186. https://doi.org/10.1111/bph.15753
Dean J, Keshavan M. The neurobiology of depression: An integrated view. Asian J Psychiatr. 2017;27:101-111. https://doi.org/10.1016/j.ajp.2017.01.025
Aggarwal S, Mortensen OV. Overview of Monoamine Transporters. Curr Protoc Pharmacol. 2017;79:12.16.1-12.16.17. https://doi.org/10.1002/cpph.32
Lee S, Paz-Filho G, Mastronardi C, et al. Is increased antidepressant exposure a contributory factor to the obesity pandemic? Transl Psychiatry. 2016;6:e759. https://doi.org/10.1038/tp.2016.25
Nakamura S. Integrated pathophysiology of schizophrenia, major depression, and bipolar disorder as monoamine axon disorder. Front Biosci (Schol Ed). 2022;14(1):4. https://doi.org/10.31083/j.fbs1401004
Thomas SJ, Shin M, McInnis MG, et al. Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: strategies for the management of treatment-resistant depression. Pharmacotherapy. 2015;35(4):433-449. https://doi.org/10.1002/phar.1576
Jesulola E, Micalos P, Baguley IJ. Understanding the pathophysiology of depression: From monoamines to the neurogenesis hypothesis model — are we there yet? Behav Brain Res. 2018;341:79-90. https://doi.org/10.1016/j.bbr.2017.12.025
Gerhard DM, Wohleb ES, Duman RS. Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity. Drug Discov Today. 2016;21(3):454-464. https://doi.org/10.1016/j.drudis.2016.01.016
Van den Eynde V, Godet L, Trupin S, et al. Classic Monoamine Oxidase Inhibitors for Depression: Update on Nursing Care. Issues Ment Health Nurs. 2023;44(2):138-139. https://doi.org/10.1080/01612840.2022.2149908
GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204-1222. https://doi.org/10.1016/S0140-6736(20)30925-9
Holmes SE, Abdallah C, Esterlis I. Imaging synaptic density in depression. Neuropsychopharmacology. 2023;48(1):186-190. https://doi.org/10.1038/s41386-022-01368-4
Popoli M, Yan Z, McEwen BS, et al. The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission. Nat Rev Neurosci. 2011;13(1):22-37. https://doi.org/10.1038/nrn3138
Luscher B, Shen Q, Sahir N. The GABAergic deficit hypothesis of major depressive disorder. Mol Psychiatry. 2011;16(4):383-406. https://doi.org/10.1038/mp.2010.120
Sanacora G, Treccani G, Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology. 2012;62(1):63-77. https://doi.org/10.1016/j.neuropharm.2011.07.036
Sanacora G, Zarate CA, Krystal JH, et al. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov. 2008;7(5):426-437. https://doi.org/10.1038/nrd2462
Lener MS, Niciu MJ, Ballard ED, et al. Glutamate and Gamma-Aminobutyric Acid Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine. Biol Psychiatry. 201715;81(10):886-897. https://doi.org/10.1016/j.biopsych.2016.05.005
Wilkinson ST, Sanacora G. A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems. Drug Discov Today. 2019;24(2):606-615. https://doi.org/10.1016/j.drudis.2018.11.007
Ghosal S, Hare B, Duman RS. Prefrontal Cortex GABAergic Deficits and Circuit Dysfunction in the Pathophysiology and Treatment of Chronic Stress and Depression. Curr Opin Behav Sci. 2017;14:1-8. https://doi.org/10.1016/j.cobeha.2016.09.012
Deutschenbaur L, Beck J, Kiyhankhadiv A, et al. Role of calcium, glutamate and NMDA in major depression and therapeutic application. Prog Neuropsychopharmacol Biol Psychiatry. 2016;64:325-333. https://doi.org/10.1016/j.pnpbp.2015.02.015
Li Z, Zhang Y, Wang Z, et al. The role of BDNF, NTRK2 gene and their interaction in development of treatment-resistant depression: data from multicenter, prospective, longitudinal clinic practice. J Psychiatr Res. 2013;47(1):8-14. https://doi.org/10.1016/j.jpsychires.2012.10.003
Keller J, Gomez R, Williams G, et al. HPA axis in major depression: cortisol, clinical symptomatology and genetic variation predict cognition. Mol Psychiatry. 2017;22(4):527-536. https://doi.org/10.1038/mp.2016.120
Kadriu B, Musazzi L, Henter ID, et al. Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments. Int J Neuropsychopharmacol. 2019;22(2):119-135. https://doi.org/10.1093/ijnp/pyy094
Duman RS, Sanacora G, Krystal JH. Altered Connectivity in Depression: GABA and Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments. Neuron. 2019;102(1):75-90. https://doi.org/10.1016/j.neuron.2019.03.013
Henter ID, Park LT, Zarate CA Jr. Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status. CNS Drugs. 2021;35(5):527-543. https://doi.org/10.1007/s40263-021-00816-x
Dean RL, Hurducas C, Hawton K, et al. Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder. Cochrane Database Syst Rev. 2021;9(9):CD011612. https://doi.org/10.1002/14651858.CD011612.pub3
Lima TM, Visacri MB, Aguiar PM. Use of ketamine and esketamine for depression: an overview of systematic reviews with meta-analyses. Eur J Clin Pharmacol. 2022;78(3):311-338. https://doi.org/10.1007/s00228-021-03216-8
Nikayin S, Murphy E, Krystal JH, et al. Long-term safety of ketamine and esketamine in treatment of depression. Expert Opin Drug Saf. 2022;21(6):777-787. https://doi.org/10.1080/14740338.2022.2066651
Fountoulakis KN, Kelsoe JR, Akiskal H. Receptor targets for antidepressant therapy in bipolar disorder: an overview. J Affect Disord. 2012;138(3):222-238. https://doi.org/10.1016/j.jad.2011.04.043
Chen MH, Cheng CM, Gueorguieva R, et al. Maintenance of antidepressant and antisuicidal effects by D-cycloserine among patients with treatment-resistant depression who responded to low-dose ketamine infusion: a double-blind randomized placebo-control study. Neuropsychopharmacology. 2019;44(12):2112-2118. https://doi.org/10.1038/s41386-019-0480-y
Karakatsoulis GN, Fountoulakis KN. The Glutamatergic System as a Target for the Development of New Pharmacological Treatments of Bipolar Disorder. In: Pavlovic Z.M., eds. Glutamate and Neuropsychiatric Disorders [Internet]. Springer International Publishing; 2022;261-282. https://doi.org/10.1007/978-3-030-87480-3_8
Murphy N, Ramakrishnan N, Vo-Le B, et al. A randomized cross-over trial to define neurophysiological correlates of AV-101 N-methyl-D-aspartate receptor blockade in healthy veterans. Neuropsychopharmacology. 2021;46(4):820-827. https://doi.org/10.1038/s41386-020-00917-z
Scala M, Fanelli G, De Ronchi D, et al. Clinical specificity profile for novel rapid acting antidepressant drugs. Int Clin Psychopharmacol. 2023;38(5):297-328. https://doi.org/10.1097/YIC.0000000000000488
Zanos P, Piantadosi SC, Wu HQ, et al. The Prodrug 4-Chlorokynurenine Causes Ketamine-Like Antidepressant Effects, but Not Side Effects, by NMDA/GlycineB-Site Inhibition. J Pharmacol Exp Ther. 2015;355(1):76-85. https://doi.org/10.1124/jpet.115.225664
Henter ID, de Sousa RT, Zarate CA Jr. Glutamatergic Modulators in Depression. Harv Rev Psychiatry. 2018;26(6):307-319. https://doi.org/10.1097/HRP.0000000000000183
Park LT, Kadriu B, Gould TD, et al. A Randomized Trial of the N-Methyl-d-Aspartate Receptor Glycine Site Antagonist Prodrug 4-Chlorokynurenine in Treatment-Resistant Depression. Int J Neuropsychopharmacol. 2020;23(7):417-425. https://doi.org/10.1093/ijnp/pyaa025
Fasipe OJ. The emergence of new antidepressants for clinical use: Agomelatine paradox versus other novel agents. IBRO Rep. 2019;6:95-110. https://doi.org/10.1016/j.ibror.2019.01.001
Dang YH, Ma XC, Zhang JC, et al. Targeting of NMDA receptors in the treatment of major depression. Curr Pharm Des. 2014;20(32):5151-5159. https://doi.org/10.2174/1381612819666140110120435
Park M, Niciu MJ, Zarate CA Jr. Novel Glutamatergic Treatments for Severe Mood Disorders. Curr Behav Neurosci Rep. 2015;2(4):198-208. https://doi.org/10.1007/s40473-015-0050-5
Zhang K, Yao Y, Hashimoto K. Ketamine and its metabolites: Potential as novel treatments for depression. Neuropharmacology. 2023;222:109305. https://doi.org/10.1016/j.neuropharm.2022.109305
Jawad MY, Di Vincenzo JD, Badulescu S, et al. The therapeutic role of ketamine and esketamine in treating psychopathological domains of depression. Neuropharmacology. 2023;223:109299. https://doi.org/10.1016/j.neuropharm.2022.109299
He T, Wang D, Wu Z, et al. A bibliometric analysis of research on (R)-ketamine from 2002 to 2021. Neuropharmacology. 2022;218:109207. https://doi.org/10.1016/j.neuropharm.2022.109207
Zhang JC, Li SX, Hashimoto K. R (-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine. Pharmacol Biochem Behav. 2014;116:137-141. https://doi.org/10.1016/j.pbb.2013.11.033
Yang C, Zhou W, Li X, et al. A bright future of researching AMPA receptor agonists for depression treatment. Expert Opin Investig Drugs. 2012;21(5):583-584; author reply 584-585. https://doi.org/10.1016/j.neuropharm.2022.109207
Fukumoto K, Toki H, Iijima M, et al. Antidepressant Potential of (R)-Ketamine in Rodent Models: Comparison with (S)-Ketamine. J Pharmacol Exp Ther. 2017;361(1):9-16. https://doi.org/10.1124/jpet.116.239228
Paul R, Schaaff N, Padberg F, et al. Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: report of two cases. World J Biol Psychiatry. 2009;10(3):241-244. https://doi.org/10.1080/15622970701714370
Can A, Zanos P, Moaddel R, et al. Effects of Ketamine and Ketamine Metabolites on Evoked Striatal Dopamine Release, Dopamine Receptors, and Monoamine Transporters. J Pharmacol Exp Ther. 2016;359(1):159-170. https://doi.org/10.1124/jpet.116.235838
Fava M, Stahl S, Pani L, et al. REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial. Am J Psychiatry. 2022;179(2):122-131. https://doi.org/10.1176/appi.ajp.2021.21020197
Ghaemi N, Sverdlov A, Shelton R, Litman R. Efficacy and safety of mij821 in patients with treatment-resistant depression: Results from a randomized, placebo-controlled, proof-of-concept study. Eur Psychiatry. 2021;64(suppl 1):S334-335. https://doi.org/10.1192/j.eurpsy.2021.897
Gomez-Mancilla B, Levy JA, Ganesan S, et al. MIJ821 (onfasprodil) in healthy volunteers: First-in-human, randomized, placebo-controlled study (single ascending dose and repeated intravenous dose). Clin Transl Sci. 2023;16(11):2236-2252. https://doi.org/10.1111/cts.13623
Shamabadi A, Ahmadzade A, Aqamolaei A, et al. Ketamine and Other Glutamate Receptor Modulating Agents for Treatment-Resistant Depression: A Systematic Review of Randomized Controlled Trials. Iran J Psychiatry. 2022;17(3):320-340. https://doi.org/10.18502/ijps.v17i3.9733
Lei T, Dong D, Song M, et al. Rislenemdaz treatment in the lateral habenula improves despair-like behavior in mice. Neuropsychopharmacology. 2020;45(10):1717-1724. https://doi.org/10.1038/s41386-020-0652-9
Diering GH, Huganir RL. The AMPA Receptor Code of Synaptic Plasticity. Neuron. 2018;100(2):314-329. https://doi.org/10.1016/j.neuron.2018.10.018
Aleksandrova LR, Phillips AG. Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics. Trends Pharmacol Sci. 2021;42(11):929-942. https://doi.org/10.1016/j.tips.2021.08.003
Suzuki A, Hara H, Kimura H. Role of the AMPA receptor in antidepressant effects of ketamine and potential of AMPA receptor potentiators as a novel antidepressant. Neuropharmacology. 2023;222:109308. https://doi.org/10.1016/j.neuropharm.2022.109308
Dijkstra F, O’Donnell P, Klaassen E, et al. Central nervous system effects of TAK-653, an investigational alpha-amino-3-hydroxy-5-methyl-4-isoxazole receptor (AMPAR) positive allosteric modulator in healthy volunteers. Transl Psychiatry. 2022;12(1):408. https://doi.org/10.1038/s41398-022-02148-w
Gordillo-Salas M, Pascual-Antón R, Ren J, et al. Antidepressant-Like Effects of CX717, a Positive Allosteric Modulator of AMPA Receptors. Mol Neurobiol. 2020;57(8):3498-3507. https://doi.org/10.1007/s12035-020-01954-x
Warner-Schmidt JL, Chen EY, Zhang X, et al. A role for p11 in the antidepressant action of brain-derived neurotrophic factor. Biol Psychiatry. 2010;68(6):528-535. https://doi.org/10.1016/j.biopsych.2010.04.029
Rosa PB, Bettio LEB, Neis VB, et al. Antidepressant-like effect of guanosine involves activation of AMPA receptor and BDNF/TrkB signaling. Purinergic Signal. 2021;17(2):285-301. https://doi.org/10.1007/s11302-021-09779-6

Закрыть метаданные